Konference: 2015 20th Congress of the European Hematology Association - účast ČR
Kategorie: Mnohočetný myelom
Téma: Multiple myeloma: Clinical studies 1
Číslo abstraktu: S107
Autoři: Prof. MUDr. Marek Trněný, CSc.; MD Thierry Lamy; MD Jan Andrzej Walewski, Ph.D.; MUDr. David Belada, Ph.D.; prof. MUDr. Jiří Mayer, CSc.; Prof. M.D. John Radford; Wojciech Jurczak; MD Franck Morschhauser, PhD; Julia Alexeeva; prof. Simon A. Rule; Tsvetan Nikolov Biyukov; Meera Patturajan; Marie-Laure Casadebaig Bravo; Luca Arcaini
Background
Clinically meaningful and statistically significant improved
activity was shown for lenalidomide, an immunomodulator with
antineoplastic and antiproliferative effects, over single-agent
investigator choice (IC) treatment in the MCL-002 (SPRINT) study of
relapsed/refractory (R/R) patients with mantle cell lymphoma
(MCL).
Aims
Evaluate the potential impact of prior therapy on progression-free
survival (PFS) in R/R MCL patients randomized to lenalidomide vs
IC.
Methods
Patients were randomized to lenalidomide (25 mg/day PO on days
1-21/28 days) or single-agent IC (rituximab, gemcitabine,
fludarabine, chlorambucil, or cytarabine). The primary endpoint of
this phase II study was PFS; prespecified exploratory analyses of
PFS by subgroups were conducted.
Results
Following a median of 2 prior therapies, 254 R/R MCL patients were
randomized 2:1 to lenalidomide (n=170) or IC (n=84). The preferred
single-agent IC therapy was selected for each patient prior to
randomization. Overall, the median PFS was significantly improved
for lenalidomide vs IC (8.7 vs 5.2 months; HR=0.61,
P=0.004). Exploratory analysis of PFS by central review
based on selected IC treatment showed that lenalidomide provided a
reduction in the risk of progression or death vs each IC treatment.
Compared with lenalidomide and taking into account small patient
numbers per IC group, the risk reduction in PFS was 22% vs
rituximab (n=27), 56% vs gemcitabine (n=20), 42% vs fludarabine
(n=18), 43% vs chlorambucil (n=11), and 8% vs cytarabine (n=8).
Subgroup analysis of PFS by central review based on prior
treatment-related subgroups favored the use of lenalidomide
overall. Several subgroups showed statistically improved PFS for
lenalidomide over IC, including patients with ≥2 prior systemic
antilymphoma therapies, >1 prior relapse, refractory to last
prior treatment, prior rituximab exposure, no prior
hyperCVAD±rituximab or stem cell transplantation, ≥6 months time
from last therapy (≥230 days from last prior rituximab), and <3
years from diagnosis to study treatment. The only category without
risk reduction (but statistically insignificant) was ≥4 prior
systemic antilymphoma therapies, partly explained by low patient
numbers in each arm.
Treatment group was the main effect associated with significantly
better PFS by univariate Cox regression analysis (HR=0.619;
P=0.004), and was highly significant in the multivariate
analysis (HR=0.384). Other factors associated with significantly
better PFS by both univariate and multivariate analysis were <3
prior systemic antilymphoma therapies, and ≥230 days from last
prior rituximab.
Summary
Subgroup and regression analyses of the primary study endpoint PFS
showed superiority for lenalidomide over IC therapy in providing
consistent clinical benefit in patients with R/R MCL irrespective
of prior treatment history.
Keyword(s): Imids, Mantle cell lymphoma
Datum přednesení příspěvku: 12. 6. 2015